Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer (Nature, (2015), 520, 7549, (697-701), 10.1038/nature14418);TP53 loss creates therapeutic vulnerability in colorectal cancer

Nature

Volumn 520, Issue 7549, 2015, Pages 697-701

  Liu, Yunhua ^a   Zhang, Xinna ^a   Han, Cecil ^a   Wan, Guohui ^a   Huang, Xingxu ^b   Ivan, Cristina ^a   Jiang, Dahai ^a   Rodriguez Aguayo, Cristian ^a   Lopez Berestein, Gabriel ^a   Rao, Pulivarthi H ^c   Maru, Dipen M ^a   Pahl, Andreas ^d   He, Xiaoming ^e   Sood, Anil K ^a   Ellis, Lee M ^a   Anderl, Jan ^d   Lu, Xiongbin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SHANGHAITECH UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Wilex Biotechnology GmbH   (Germany)

^e Ohio State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMANITIN; ANTINEOPLASTIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HEA 125; PROTEIN P53; RNA POLYMERASE II; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIBODY; ANTIBODY CONJUGATE; CELL ADHESION MOLECULE; PROTEIN SUBUNIT; TUMOR ANTIGEN;

CANCER; GENE EXPRESSION; GENOMICS; MUTATION; SIGNALING; TOXICITY; TUMOR; VULNERABILITY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE REPRESSION; HEMIZYGOSITY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; COLORECTAL NEOPLASMS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETIC DATABASE; GENETICS; IMMUNOLOGY; PATHOLOGY; PROTEIN SUBUNIT; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ALPHA-AMANITIN; ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CATALYTIC DOMAIN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DATABASES, GENETIC; DISEASE MODELS, ANIMAL; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; GENE DELETION; GENE DOSAGE; GENES, P53; HUMANS; IMMUNOCONJUGATES; MICE; PROTEIN SUBUNITS; RNA POLYMERASE II; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928788044     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-021-03664-3     Document Type: Erratum

References (28)

1. Petitjean, A. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622-629 (2007).
2. Vazquez, A. et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Rev. Drug Discov. 7, 979-987 (2008).
3. Cheok, C. F. et al. Translating p53 into the clinic. Nature Rev. Clin. Oncol. 8, 25-37 (2011).
4. Lane, D. P., Cheok, C. F. & Lain, S. p53-based cancer therapy. Cold Spring Harb. Perspect. Biol. 2, a001222 (2010).
5. Chène, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102-109 (2003).
6. Wade, M., Li, Y. C.& Wahl, G. M. MDM2, MDMXand p53 in oncogenesis and cancer therapy. Nature Rev. Cancer 13, 83-96 (2013).
7. Haupt, S. & Haupt, Y. Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin. Cancer Biol. 14, 244-252 (2004).
8. Bensaude, O. Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription 2, 103-108 (2011).
9. Lindell, T. J. et al. Specific inhibition of nuclear RNA polymerase II by a-amanitin. Science 170, 447-449 (1970).
10. Letschert, K. et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 91, 140-149 (2006).
11. Moldenhauer, G. et al. Therapeutic potential ofamanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 104, 622-634 (2012).
12. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nature Rev. Mol. Cell Biol. 11, 220-228 (2010).
13. Nijhawan, D. et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150, 842-854 (2012).
14. Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337-342 (2012).
15. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
16. Toledo, F. & Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Rev. Cancer 6, 909-923 (2006).
17. Wang, T. et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
18. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013).
19. Derheimer, F. A. et al. RPA and ATR link transcriptional stress to p53. Proc. Natl Acad. Sci. USA 104, 12778-12783 (2007).
20. Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171-185 (2013).
21. Faulstich, H. Fiume, L. Proteinconjugates of fungal toxins. Methods Enzymol. 112, 225-237 (1985).
22. Went, P. T. et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35, 122-128 (2004).
23. Pecot, C. V. et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol. Cancer Ther. 13, 2876-2885 (2014).
24. Goldstein, I. et al. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 18, 2-11 (2011).
25. Liu, Y. et al. Kaposi's sarcoma-associated herpesvirus-encoded microRNA miRK12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J. Virol. 86, 1372-1381 (2012).
26. Cong, L. et al. Multiplex genomeengineering usingCRISPR/Cas systems. Science 339, 819-823 (2013).
27. Guschin, D. Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247-256 (2010).
28. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8, 2281-2308 (2013).